Eupraxia continues to observe positive treatment outcomes in its ongoing Phase 1b/2a trial, including for the first time clinical responses measured 9 months after dosing with EP-104GI At 9 months ...

APT-1011 is a novel, proprietary, once daily, investigational oral disintegrating tablet designed to deliver fluticasone propionate to the esophageal mucosa while minimizing residence time in the oral ...

The ongoing study could influence Regeneron and Sanofi’s market positions by providing valuable insights into DUPIXENT®’s ...

Dupixent ® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE) Approval based on Phase 3 EoE KIDS trial showing a greater ...

Eupraxia Pharmaceuticals shares rose in premarket trading Tuesday after the company said it received positive data from its eosinophilic esophagitis treatment trials. Shares traded nearly 6.3% higher ...

VICTORIA, British Columbia, May 05, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its ...